Carcinoma, Non-Small-Cell Lung Clinical Trial
— Chrysalis-2Official title:
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to confirm the tolerability of recommended Phase 2 dose (RP2D) of Lazertinib (Phase 1), to determine the tolerability and identify the recommended Phase 2 combination dose of Lazertinib when combined with Amivantamab (JNJ-61186372) (Phase 1b), to characterize the safety and tolerability of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced non-small cell lung cancer (NSCLC) with documented advanced or metastatic epidermal growth factor receptor (EGFR) mutation (Phase 1b expansion cohorts A, B, C, D and E), to estimate the antitumor activity of Lazertinib and Amivantamab combinations at the RP2CD in participants with advanced NSCLC with documented advanced or metastatic EGFR mutation (Phase 1b expansion cohorts A, B, C, and D), to validate the biomarker identified in Phase 1b expansion Cohort D as a predictor of antitumor activity of Lazertinib and Amivantamab combination (Cohort E) or Amivantamab monotherapy (Cohort F) in participants with osimertinib-relapsed, chemotherapy-naïve, EGFR Exon19del or L858R mutated NSCLC, to identify the recommended Phase 2 dose (RP2ChD) of Lazertinib when combined with Amivantamab and standard of care chemotherapy and to determine the tolerability of the Lazertinib, Amivantamab, and platinum-doublet chemotherapy (LACP) combination (Phase 1b LACP combination cohort) and to characterize the safety and tolerability of Lazertinib at the RP2ChD and Amivantamab and standard of care chemotherapy in participants with advanced or metastatic EGFR-mutated NSCLC (Phase 1b LACP combination cohort), to assess 2 potential biomarker strategies to identify participants at increased, or decreased, probability of tumor response with JNJ-61186372 and lazertinib combination in participants with EGFR Exon19del or L858R mutated NSCLC progressed on or after osimertinib (Phase 1b expansion Cohort D).
Status | Recruiting |
Enrollment | 460 |
Est. completion date | February 14, 2027 |
Est. primary completion date | February 3, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Phase 1 and Phase 1b lazertinib+Amivantamab combination cohorts: Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with previously epidermal growth factor receptor (EGFR) mutation (identified locally in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory [or equivalent]) that is metastatic or unresectable, and have progressed after standard of care front-line therapy, and exhausted available options with targeted therapy. A participant who has refused all other currently available therapeutic options is allowed to enroll - For the Phase 1b Lazertinib, Amivantamab and Platinum-doublet Chemotherapy (LACP) combination cohort: histologically or cytologically confirmed advanced or metastatic EGFR-mutated NSCLC who have progressed on or after an EGFR-TKI as the most recent line of treatment with a maximum of 3 prior lines of therapy in the metastatic setting allowed - For all expansion cohorts, the EGFR mutation must have been previously histologically or cytologically characterized, as performed by a CLIA-certified (US sites) or an accredited (outside of US) local laboratory, with a copy of the mutation analysis being submitted during screening (Phase 1b expansion Cohort B, C, D, E, and F) 1. Expansion Cohort A: Participant must have advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) that has progressed on prior treatment with osimertinib in the first or second line, followed by progression on a platinum-based chemotherapy regimen as the last line of therapy prior to study enrollment. Prior use of first or second generation EGFR tyrosine kinase inhibitor (TKI) is allowed if administered prior to osimertinib 2. Expansion Cohort B: Participant must have previously treated, advanced or metastatic NSCLC with documented primary EGFR Exon 20ins activating mutation. Participants should have been treated with standard of care, platinum-based chemotherapy regimens, but may have treated with approved EGFR TKI, investigational EGFR, or immunotherapy agents if refusing front line platinum-based chemotherapy standard of care. Up to 3 lines of prior systemic anti-cancer treatment are allowed 3. Expansion Cohort C: Participant must have advanced or metastatic NSCLC characterized by an uncommon activating mutation Additional uncommon EGFR mutations/alterations, beyond those listed above, may be considered for enrollment after agreement with the medical monitor. Participants may be treatment naïve or have been treated with one prior line of therapy which must be a first or second generation TKI (that is gefitinib, erlotinib, afatinib) in the most recent line of therapy. Prior chemotherapy is allowed if administered prior to EGFR TKI therapy, or as the only systemic anti-cancer therapy prior to study enrollment. Up to 2 lines of prior systemic anti-cancer treatment are allowed 4. Expansion Cohort D, E, and F: Participant must have advanced or metastatic EGFR-mutated NSCLC (EGFR Exon19 deletion or L858R) that has progressed on prior treatment with osimertinib in the first or second line (after first- or second-generation EGFR TKI), as the immediate prior line of therapy. Only previous treatment in the metastatic setting with a first, second, or third generation EGFR TKI is allowed. In addition, participants considered for Cohorts E and F must be eligible for, and agree to comply with, the use of prophylactic anticoagulation with a direct oral anticoagulant or a low molecular weight heparin during the first 4 months (from Day 1 through Day 120) according to national comprehensive cancer network (NCCN) or local guidelines, if assigned to the combination Cohort E - Evaluable disease - Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1 - Participants must meet the study protocol defined laboratory criteria without having a history of red blood cell transfusion, platelet transfusion, or granulocyte-colony stimulating factor support within 7 days prior to the date of the test - A woman of childbearing potential: Must have a negative serum beta human chorionic gonadotropin at screening; Must agree not to breast-feed during the study and for 6 months after the last dose of study intervention. (Enrollment is not allowed even if a woman who is breast-feeding stops breast-feeding); Must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study intervention Exclusion Criteria: - Participant has an uncontrolled illness, including but not limited to uncontrolled diabetes, ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to study treatment] or diagnosed or suspected viral infection); active bleeding diathesis; Impaired oxygenation requiring continuous oxygen supplementation; Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of study treatment; or psychiatric illness or any other circumstances (including social circumstances) that would limit compliance with study requirements. Any ophthalmologic condition that is either clinically unstable or requires treatment - Prior treatment with anti programmed cell death-1 (PD-1) or anti programmed cell death-ligand 1 (PD-L1) antibody within 6 weeks of planned first dose of study intervention - Untreated brain or other central nervous system (CNS) metastases whether symptomatic or asymptomatic. Participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment may be eligible for Phase 1b expansion cohorts. If brain metastases are diagnosed on Screening imaging, the participant may be enrolled, or rescreened for eligibility, after definitive treatment if above criteria are met - Any Toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade <=2 peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement therapy) - Allergies, hypersensitivity, or intolerance to Lazertinib or JNJ-61186372 or their excipients. For the LACP combination cohort: participant has a contraindication for the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid |
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | |
China | The First Bethune Hospital of Jilin University | Changchun | |
China | Hunan Cancer hospital | Changsha | |
China | West China School of Medicine/West China Hospital, Sichuan University | Chengdu | |
China | Chongqing University Cancer Hospital | Chongqing | |
China | The Fifth Affiliated Hospital of Guangzhou Medical University | Guangzhou | |
China | Zhejiang Cancer Hospital | Hang Zhou | |
China | Central Hospital of Jinan | Jinan | |
China | The Second Affiliated Hospital of Kunming Medical University | Kunming | |
China | Shanghai Chest Hospital | Shanghai | |
China | Shengjing Hospital Of China Medical University | Shenyang | |
China | Tianjin Medical University Cancer Institute and Hospital | Tianjin | |
China | Union Hospital Tongji Medical College of Huazhong University of Science and Technology | Wuhan | |
China | The First Affiliated Hospital of Xian Jiaotong University | Xian | |
France | Institut Bergonie | Bordeaux | |
France | Centre Leon Berard | Lyon Cedex 8 | |
France | CHU de la Timone | Marseille | |
France | Institut Curie | Paris | |
France | CHU De Poitiers | Poitiers | |
France | HIA Begin | Saint Mande | |
France | Institut Gustave Roussy | Villejuif Cedex | |
Germany | Evangelische Lungenklinik Berlin | Berlin | |
Germany | Universitaetsklinikum Essen | Essen | |
Germany | Klinikum der Johann Wolfgang Goethe-Universität | Frankfurt am Main | |
Germany | Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting | Gauting | |
Germany | Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH | Halle (Saale) | |
Germany | Lungenklinik Hemer | Hemer | |
Germany | Kliniiken der Stadt Köln gGmbH, Krankenhaus Köln-Mehrheim | Köln | |
Germany | Uniklinik Köln | Köln | |
Germany | Pius-Hospital Oldenburg | Oldenburg | |
Germany | Robert-Bosch-Krankenhaus - Klinik Schillerhoehe | Stuttgart | |
Italy | IRCCS Istituto Europeo di Oncologia | Milano | |
Italy | IRCCS Ospedale San Raffaele | Milano | |
Italy | San Gerardo Hospital | Monza | |
Italy | Istituto Nazionale Tumori Fondazione G. Pascale | Napoli | |
Italy | Ospedale S. Maria Delle Croci | Ravenna | |
Japan | National Cancer Center Hospital | Chuo Ku | |
Japan | Kansai Medical University Hospital | Hirakata | |
Japan | National Cancer Center Hospital East | Kashiwa | |
Japan | Kobe City Medical Center General Hospital | Kobe City | |
Japan | Aichi Cancer Center Hospital | Nagoya Shi | |
Japan | Okayama University Hospital | Okayama | |
Japan | Shizuoka Cancer Center | Shizuoka | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam-si | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | Severance Hospital Yonsei University Health System | Seoul | |
Puerto Rico | Oncologic Hospital, Puerto Rico Medical Center | Rio Piedras | |
Spain | Hosp. Univ. Quiron Dexeus | Barcelona | |
Spain | Hosp. Univ. Vall D Hebron | Barcelona | |
Spain | Hosp Univ Fund Jimenez Diaz | Madrid | |
Spain | Hosp. Gral. Univ. Gregorio Maranon | Madrid | |
Spain | Hosp. Univ. 12 de Octubre | Madrid | |
Spain | Hosp. Univ. Hm Sanchinarro | Madrid | |
Spain | Hosp. Univ. Ramon Y Cajal | Madrid | |
Spain | Hosp. Virgen Del Rocio | Seville | |
Taiwan | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | Chung Shan Medical University Hospital | Taichung | |
Taiwan | National Cheng Kung University Hospital | Tainan | |
Taiwan | National Taiwan University Hospital | Taipei City | |
United States | Boston University Medical Center | Boston | Massachusetts |
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Barbara Ann Karmanos Cancer Institute | Detroit | Michigan |
United States | Virginia Cancer Specialists | Fairfax | Virginia |
United States | USC - Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Columbia University Medical Center | New York | New York |
United States | Langone Health at NYC University, NYU School of Medicine | New York | New York |
United States | University of California Irvine | Orange | California |
United States | University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine | Philadelphia | Pennsylvania |
United States | Providence Portland Medical Center | Portland | Oregon |
United States | Washington University School Of Medicine | Saint Louis | Missouri |
United States | Huntsman Cancer Institute | Salt Lake City | Utah |
United States | UCSF Helen Diller Comprehensive | San Francisco | California |
United States | University of Washington | Seattle | Washington |
United States | Stanford University Medical Center | Stanford | California |
United States | H. Lee Moffitt Cancer & Research Institute | Tampa | Florida |
United States | Cedars Sinai Medical Center | West Hollywood | California |
Lead Sponsor | Collaborator |
---|---|
Janssen Research & Development, LLC |
United States, China, France, Germany, Italy, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1) | DLTs are defined as certain non-hematologic and hematologic toxicities of Grade 3 or higher. | Until the end of first cycle (21 days for Phase 1) | |
Primary | Percentage of Participants with Dose-Limiting Toxicity (DLT) (Phase 1b) | DLTs are defined as certain non-hematologic and hematologic toxicities of Grade 3 or higher. | Until the end of first cycle (28 days for Phase 1b) | |
Primary | Overall Response Rate (ORR) (Phase 1b Expansion Cohorts A-D) | ORR is defined as the percentage of participants who achieve either a complete (CR) or partial response (PR) as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Primary | Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability (Phase 1b Expansion Cohorts A-E) | Adverse events (AEs) defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Criteria Version 5.0 in participants treated at the RP2CD regimen of Lazertinib and Amivantamab combination therapy. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. | Up to 2.5 years | |
Primary | Percentage of Participants with DLT (Phase 1b combination Lazertinib, Amivantamab, Platinum-doublet chemotherapy [LACP]) | DLTs are defined as certain non-hematologic and hematologic toxicities of Grade 3 or higher. | Until the end of first cycle (21 days for Phase 1b combination LACP) | |
Primary | Number of Participants with AEs as a Measure of Safety and Tolerability (Phase 1b combination LACP) | AEs defined by the NCI-CTCAE criteria version 5.0 in participants treated with LACP combination regimen. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. | Up to 2.5 years | |
Primary | Overall Response Rate (ORR) per RECIST version 1.1 (v1.1) with NGS Analysis of Circulating Tumor ctDNA, IHC Analysis of EGFR and MET Expression (Phase 1b Expansion Cohort D) | ORR is defined as the percentage of participants who achieve either a complete (CR) or partial response (PR) as determined by the investigator using RECIST 1.1 criteria with Next Generation Sequencing (NGS) Analysis of Circulating Tumor Deoxyribonucleic Acid (ctDNA), Immunohistochemical (IHC) Analysis of Tumor Epidermal Growth Factor Receptor (EGFR) and MET Expression (Phase 1b Expansion Cohort D). | Up to 2.5 years | |
Primary | ORR Among Participants with MET3+ Staining on Greater Than or Equal to (>=)25 Percent (%) of Tumor Cells (Phase 1b Expansion Cohorts E and F) | ORR among participants with MET3+ staining on >=25 % of tumor cells will be reported. ORR is defined as the percentage of participants who achieve either a CR or PR as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Primary | Duration of Response (DOR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F) | DOR among participants with MET3+ staining on >=25 % of tumor cells will be reported. DOR will be calculated as time from initial response of CR or PR to progressive disease (PD) or death due to any cause, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Primary | Clinical Benefit Rate (CBR) Among Participants with MET3+ Staining on >=25% of Tumor Cells (Phase 1b Expansion Cohorts E and F) | CBR among participants with MET3+ staining on >=25% of tumor cells will be reported. CBR is defined as the percentage of participants achieving complete or partial response, or durable stable disease (duration of at least 11 weeks) as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability (Phase 1 and Phase 1b) | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. | Up to 2.5 years | |
Secondary | Plasma Concentration of Lazertinib (Phase 1 and Phase 1b) | Plasma samples will be analyzed to determine concentrations of Lazertinib. | Up to End of Treatment [EOT]) (30 days after last dose) (up to 2.5 years) | |
Secondary | Serum Concentration of Amivantamab (Phase 1b) | Serum samples will be analyzed to determine concentrations of Amivantamab. | Up to EOT (30 days after last dose) (up to 2.5 years) | |
Secondary | Number of Participants with Anti-drug Antibodies Against Amivantamab (Phase 1b) | Number of participants with anti-drug antibodies against Amivantamab will be reported. | Up to EOT (30 days after last dose) (up to 2.5 years) | |
Secondary | Progression free survival (PFS) (Phase 1b Expansion) | PFS is defined as the time from first infusion of study intervention to PD or death due to any cause. | Up to 2.5 years | |
Secondary | Time to Treatment Failure (TTF) (Phase 1b Expansion) | TTF is defined as the time from the first administration of the study intervention to discontinuation of treatment for any reason, including disease progression, treatment toxicity, death, and will be utilized to capture clinical benefit for patients continuing treatment beyond as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | Overall Survival (OS) (Phase 1b Expansion) | OS is defined as the time from first infusion of study intervention to death due to any cause as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | Duration of Response (DOR) (Phase 1b expansion) | DOR will be calculated as time from initial response of CR or PR to progressive disease (PD) or death due to any cause, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | Clinical Benefit Rate (CBR) (Phase 1b expansion) | CBR is defined as the percentage of participants achieving complete or partial response, or durable stable disease (duration of at least 11 weeks) as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | Number of Participants with Venous Thromboembolic (VTE) Events by Severity | Number of participants with VTE events including pulmonary embolism and deep vein thrombosis by severity defined by the NCI-CTCAE Criteria Version 5.0 will be reported. | Up to 2.5 years | |
Secondary | Number of Participants with Adverse Events (AEs) (Phase 1b Expansion Cohort F) | An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. | Up to 2.5 years | |
Secondary | ORR (Phase 1b expansion Cohorts E and F) | ORR is defined as the percentage of participants who achieve either a CR or PR as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | DOR (Phase 1b Expansion Cohorts E and F) | DOR will be calculated as time from initial response of CR or PR to PD or death due to any cause, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | CBR (Phase 1b expansion Cohorts E and F) | CBR is defined as the percentage of participants achieving complete or partial response, or durable stable disease (duration of at least 11 weeks) as determined by the investigator using RECIST 1.1 criteria. | Up to 2.5 years | |
Secondary | Intracranial Progression free survival (PFS) (Phase 1b Expansion E and F) | Intracranial PFS is defined as the time from first infusion of study intervention until the date of objective intracranial disease progression or death, whichever comes first, based on Investigator assessment using RECIST v1.1. | Up to 2.5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT04452214 -
A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors
|
Phase 1 |